Last reviewed · How we verify

NCT05038007

Pain After Lung Cancer Surgery - Comparing Traditional Versus Prolonged Release Nerve Blockades

Status unknown Phase 2 Last updated 21 September 2021
What this trial tests

Phase 2 trial testing Liposomal bupivacaine in Postoperative Pain in 50 participants. Status unknown.

Timeline
15 September 2021
Primary endpoint
1 April 2022
31 May 2022

Quick facts

Lead sponsorJannie Bisgaard Stæhr
PhasePhase 2
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment50
Start date15 September 2021
Primary completion1 April 2022
Estimated completion31 May 2022
Sites1 location across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

Jannie Bisgaard Stæhr

Who can join

18 and older, any sex, with Postoperative Pain or Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate the effect of liposomal bupivacaine compared with bupivacaine hydrochloride for intercostal blockades for patients undergoing Video-assisted thoracoscopic surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Liposomal bupivacaine

Trials testing the same drug.

Other recruiting trials for Postoperative Pain

Currently open trials in the same condition.

Other Jannie Bisgaard Stæhr trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05038007.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing